Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL491800 | 0.81 | PPARD (0.62) | PPARDTSHRTDP1TP53MEN1 | |
| SCHEMBL5001168 | 0.81 | PPARD (0.56) | PPARDTSHRTDP1TP53MEN1 | |
| SCHEMBL19091132 | 0.77 | PPARD (0.52) | PPARDTSHRTDP1TP53MEN1 | |
| SCHEMBL3313657 | 0.77 | PPARD (0.70) | PPARDTSHRTDP1TP53MEN1 | |
| SCHEMBL19594045 | 0.77 | PPARD (0.47) | PPARDTSHRTDP1TP53MEN1 | |
| SCHEMBL1666154 | 0.76 | — | — | |
| SCHEMBL15532056 | 0.74 | PPARD (0.65) | PPARDTSHRTDP1TP53MEN1 | |
| SCHEMBL11587786 | 0.74 | PPARD (0.48) | PPARDTSHRTDP1TP53MEN1 | |
| SCHEMBL10669305 | 0.74 | PPARD (0.48) | PPARDTSHRTDP1TP53MEN1 | |
| SCHEMBL20404508 | 0.74 | PPARD (0.44) | PPARDTSHRTDP1TP53MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2507249-B1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES INC (US) | 2015-11-11 | — | — | EP | disclosed |
| US-8765722-B2 | Inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20130302280-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. | 2013-11-14 | — | — | US | disclosed |
| US-8501714-B2 | Inhibitors of Flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8444820-B2 | Aqueous composition containing at least one soluble gelatinized anionic starch | ROQUETTE FRERES (FR) | 2013-05-21 | — | — | US | disclosed |
| US-20120156166-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011031669-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| US-20100243188-A1 | AQUEOUS COMPOSITION CONTAINING AT LEAST ONE SOLUBLE GELATINIZED ANIONIC STARCH | ROQUETTE FRERES (FR) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130302280-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | PPARD 824/4885TSHR 4286/4885TDP1 2424/4885 |
| US-20120156166-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | PPARD 824/4885TSHR 4286/4885TDP1 2424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.